Announcement PDF 1 Sales & Marketing Update ReNerve Board meeting | July 2025 ReNerve Quarterly Webinar presentation | November 2025 ASX:RNV Transforming Nerve Repair Through Science Important Notice & Disclaimer Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation. Not an offer: this presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be unlawful under the securities or other laws of that or any other jurisdiction. Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision. Forward looking statements: This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified by such terms as "anticipates", "believes", “should”, "could", "estimates", “target”, “likely”, “plan”, "expects", "may", “intend”, "shall", "will", or "would". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to risk factors associated with the Company’s business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. 2 Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice. An offer of Shares in ReNerve Ltd (ABN 23 614 848 216) is being made in or accompanied by a prospectus dated at a date to be confirmed. Anyone who wants to acquire Shares pursuant to the offer will need to complete the application form that accompanies the prospectus. A person should consider and rely only on the prospectus in deciding whether to invest. A copy of the prospectus is available by contacting the Company or by downloading from the Company’s website (www.renerve.com.au). Speculative nature of investment: Any potential investor should be aware that subscribing for Shares involves various risks. The Shares to be issued pursuant to the Prospectus lodged with ASIC by ReNerve Ltd carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those Shares. An investment in Shares of the Company should therefore be considered very speculative. ReNerve Ltd ABN 23 614 848 216 Executive Summary Development of Novel Nerve Repair & Regeneration Products ReNerve is developing a comprehensive portfolio of products for the nerve repair and regeneration markets and related surgical procedures, with clearly defined commercial demand. Expanding Product Portfolio 4 product ranges expected on or near market with a developing portfolio of research and development products. Strong Sales & Distribution Presence ReNerve has established logistics, warehouse and invoicing infrastructure with a strong focus on building a sales distribution network for all products in the US. Global Expansion & Commercialisation Successful ongoing expansion within the first year of ASX listing into Ex-US markets in Asia, India, The Middle East, and The Americas. Clinical & Professional Validation Improved patient outcomes for post-surgical measures of pain and surgery satisfaction, as well as proven ease of use for surgeons. 3 Quarter Highlights Launched Dermal and 3 Amniotic Tissue Product Ranges Achieved first dermal sale Achieved first sale of the amniotic tissue Targeting same surgeons and procedures as the nerve product range There to accelerate sales growth Launch of Empliq Product Range Revenue up 38% qtr on qtr Sales up 38% to corresponding qtr - Growing year on year Launch of two new product ranges Closing cash of $3.27M 21 US distributors in place Small team in the US as we build our US presence now with multiple product lines in market Supporting the 21 distributors ReNerve team to ‘hold the hands’ of distributors for new products and initial sales 4 Company Portfolio Nerve Cuff Nerve Tube Nerve Protector Nerve Guide Matrix Nerve Cap Dermal Tissue AmnioLite AmnioDuo Placental R&D Product Development Commercial Development On Market Product 5 Target Market USD$2.0Bn USD$6.0Bn Global Nerve Repair Biomaterial Market USD$1.0Bn 2025 USD$6.19Bn USD$1.90Bn USD$1.10Bn The Global Nerve Repair Biomaterials Market is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD$6.19Bn. 2031 Our Target Markets Dermal and Amniotic Tissue Surgical Applications (Trauma, plastic surgery) Dermal and Amniotic Tissue Orthopedics (Tendon and Ligament MarketWide Research – Dermal and Amniotic tissue market report 2025- 2032, Published 2025. 6 ReNerve’s Nerve Opportunity Product • Used on damaged or transected nerves with no gaps or gap closure • Improved Nerve Cuff developed from scCO2 tissue, offering better product profile • An ‘off-the-shelf’, ready to use nerve graft replacement with internal guidance infrastructure • An ‘off-the-shelf’, continuous nerve replacement, in a ready to use nerve structure Procedure Use • End to end suturing covered with a wrap/cuff • Protective cuff for grafts • Protecting injured nerve repairs • Replaces damaged nerve section instead of using donor or harvested tissue • The Bionic Nerve is a nerve guide matrix with ionic polymers designed to replace injured and damaged nerves for lengths from 1cm to 20cm Application • Trauma • Breast reconstruction • Orthopaedics • Oral & maxillofacial surgery • Trauma • Breast reconstruction • Orthopaedics • Foot and ankle • Trauma • Breast reconstruction • Orthopaedics • Hand & wrist • Trauma • Craniotomy • Spinal cord injury • Spinal cord surgery Benefit • Bio-absorbed removing need for additional surgery • Pliable and conforms • Improved product profile to Nerve Cuff • Stronger patient reimbursement • Can be cut to ideal length • Off-the-shelf, reducing logistics issues • Simple to use and cost effective • Enable production of nerves of bespoke dimension FDA Status Approved Targeting market release end ’25/H1 ‘26 Targeting H2 CY27 filing Targeting Q4 CY28 filing TAM (USD) $314m $975m 2024 2030 $635m $1991m 2024 2030 $1015m $3219m 2024 2030 >$400m 2023 Nerve Cuff Bionic Nerve Nerve Conduit Nerve Guide Matrix 7 8 01 Product Range Empliq Product Portfolio Empliq AmnioLite Empliq AmnioDuo Empliq Placental Empliq Dermal Description Single-layer amniotic membrane allograft Double-layer amniotic membrane allograft Placental allograft including amniotic membrane and chorion Deep-layer dermal matrix Clinical Value Natural barrier to protect wounds from external environment Thicker barrier for complex wounds Improved handling characteristics Natural barrier to protect wounds from external environment Additional structural support Natural scaffold for protection, reinforcement and capillary formation No basement membrane - rapid tissue ingrowth and healing Applications DFUs, VLUs, surgical wounds, vulnerable tissue DFUs, VLUs, pressure injury, surgical wounds Breast reconstruction, Tendon augmentation, abdominal wall repair, hernia repair DFU = Diabetic foot ulcer; VLU = Venous leg ulcer 9 Robust Portfolio • Expanded to 21 distributors across the US • Full logistics, warehousing and invoicing in place • Distributors will sell the ReNerve product ranges • Will add additional products as they come to market Focus surgical areas Subspecialties • Hand (upper extremity) • Breast • Lower Extremity (M.D. & DPM) • Plastics Reconstruction • Head & Neck • Spine Sales and Marketing Update US Market Expanded Distribution Channels 10 11 ReNerve Distribution Strategy Ex-US Sales & Marketing MIDDLE EAST Targeting meaningful markets such as India and Asia Leveraging off FDA approval and US patient data Will use the US data from the “Align” study for European submission Sales Highlights Indian submission completed and in final Government review. Market valued at USD$115M and growth at 18+%* Working with the local Indian partner to engage with hospitals and surgeons with extensive leads identified Aiming to expand regional approvals and sales and marketing across Asia Potential to drive revenue to complement the US business 11 Leveraging US approval and patient data for entry into global markets Asia India Progressed to final stage of approval with local pre-approval market engagement underway Expanding regional approvals and local distributor appointments Approval in Bahrain as the first step in the region. * Global Nerve Repair Biomaterials Market Research Report (2020 – 2031) 12 02 Nerve Cuff Key Features ReNerve’s “Align” Clinical Study Definitive clinical study on using NervAlign Nerve Cuff for nerve repair 120 patients per cohort Comparing standard of care vs treatment with NervAlign Nerve Cuff Clinical Use • Hundreds of patients implanted to date • Received positive feedback from surgeons stating it handles well, is pliable and conforms and has resulted in strong patient outcomes. • Has been used with attachment methods including sutures, glue, micro clips and ‘nothing’. Product • Bio-absorbed within 6-months. • Produced using a non-toxic method. • Terminally sterilised with no residual chemicals. • Covered under procedural reimbursement rather than individual product reimbursement. • Promotes vascular • Semi-translucent Patient Benefit ● Requires no change to surgical technique or procedures. ● Available in various sizes and thickness with ability to be trimmed to required shape. ● Is pliable and conforms, semi-translucent and easy to use Surgeon Benefit 3 2 1 Patient Results • Protects nerves during recovery post peripheral nerve repair • Great handling characteristics and absorbed within 6 months 13 The “Align” Study 14 Clinical Study on the NervAlign® Nerve Cuff Undertaking a definitive study in nerve repair and surgical neurolysis to show the benefit of protecting the nerve post nerve repair surgery. Study Design: Two patient cohorts • Control Group: Standard neurectomy repair • Test Group: Neurectomy repair with NervAlign Nerve Cuff • Based on the study which showed clear benefit for using the NervAlign Nerve Cuff Key Outcomes: • Looking for significance in Pain Reduction: ‒ Secondary outcomes in patient recovery ‒ Product performance in surgery • Patient follow up around 6 to 9 months Data presentation • Aiming to complete recruitment by mid 2026 • Data accumulated along the way • First 50 patients recruited to date • Data likely to be published and presented in late 2026/early 2027 Comparison of Patient Pre & Post Surgery Pain Score Standard of Care NervAlign Nerve Cuff Protected Figure 1. The comparison of pain scores between the two cohorts of patients 54% Improvement 96% Improvement 7.1 7.1 3.3 0.4 15 03 Conduit Update Conduit Update Able to make it commercially – moving to commercial material production 2 Currently doing scale up manufacturing and validation runs 1 17 04 Nerve Guide Matrix (Graft) Key Features & Guide Matrix Product • The NervAlign® Neve Guide Matrix is an ‘off- the-shelf’, ready to use nerve graft replacement with internal infrastructure. • ReNerve is developing multiple product options: - Initial ‘wet’ prep nerve graft; - Longer lengths out to 7cms+ and various diameters • Entering 3rd of 4 stages of commercial development by late ’25/ early CY’26 Current Options • Harvesting patients own nerves. • Donor tissue graft. • Conduits (for smaller repairs). • High demand need for an alternative Benefits - Doesn’t create secondary surgical site; - Stored at room temperature, removing storing issues; - Doesn’t go through Wallerian degeneration; - Ease of use allows for immediate repairs; - Longer lengths enables surgical revisions; - More cost effective to existing options; and - Positive outcomes post-surgery ReNerve Nerve Guide Matrix offers many benefits, including: 18 Near Term Milestones – 2025/2026 1H 2025 Q4 2025/Q1 2026 Near Term 27 February 2025 Partnership Signed for Mexico Market 7 March 2025 R&D Tax Incentive Refund Received 11 March 2025 Thailand Approval & First Hong Kong Sale 28 March 2025 Clinical Study Results Presented 29 April 2025 Q3 FY25 Results: Revenue Growth & Clinical Validation 10 April 2025 Partnership for Indian Market Announced NervAlign® Nerve Cuff Approvals in New Countries & Territories NervAlign® Nerve Conduit into Market (Q4 2025/Q1 2026) Growing the EmpliQ brand Initial Clinical Cases for the Nerve Conduit Nerve Guide Matrix GMP production ReNerve ‘Align’ Study data NervAlign® Nerve Cuff filing for European approval Starting GMP manufacturing (Stage 3) runs of the Nerve Guide Matrix NervAlign® Nerve Cuff approval in India Expansion of the Nerve Repair product portfolio Continued sales growth First clinical cases using the nerve guide matrix NervAlign® Nerve Cuff approval in Taiwan 19 Investment Highlights In Market Product Immediate Market Need Growing Market Diverse Product Portfolio Growing Distribution Board & Management Nerve Cuff transitioned from R&D to commercial sales post FDA market clearance, achieving strong initial product margins. Product offering promotes nerve injury recovery and regrowth leading to faster patient recovery and better outcomes. Nerve repair biomaterials and related markets are forecasted to grow by >17% pa, estimated to be worth >US$6.19Bn by 2031. Four product ranges in market by year end, all of which are already developed. Additional products currently under development. Continuing to build sales representation with a targeted-direct sales approach. Highly accomplished executive team with a proven track record in the development & commercialisation of medical opportunities. 20 ASX:RNV Contact ReNerve Limited info@renerve.com.au Level 10/99 Queen St, Melbourne, Victoria 3000 Australia +61 (03) 9482 3940 21